Prof. Peter K. Law

Cell Therapy Institute, China

Founder & Chairman

University of Tennessee Memphis, USA

Professor Emeritus

Wuhan University, China

Distinguish Professor of Oncology

Zhengzhou University, China

Professor of Pediatrics

Fifth Affiliated Hospital of Zhengzhou University, China

Visiting Professor

Email: pdlaw888@yahoo.ca

Qualifications

1972 Ph.D., University of Toronto

1969 M.Sc., University of Toronto

1968 B.Sc., McGILL University

Publications (selected)

1. Law, P.K. and H.L. Atwood. Cross-reinnervation of dystrophic mouse muscles. Nature 238:287–288, 1972.
2. Law, P.K., E. Cosmos, J. Butler and A.J. McComas. The absence of dystrophic characteristics in normal muscles successfully cross-reinnervated by nerves of dystrophic genotypes: Physiological and cytochemical study of crossed solei of normal and dystrophic parabiotic mice. Exp. Neurol. 51: 1–21, 1976.
3. Law, P.K. Reduced regenerative capability of dystrophic mouse muscle. Exp. Neurol. 60:231–243, 1978.
4. Law, P.K. and J.L. Yap. New muscle transplant method produces normal twitch tension in dystrophic muscle. Muscle & Nerve 2:356–363, 1979.
5. Law, P.K. “Leaky” membrane causes weakness in dystrophic soleus fibers. Adv. Physiol. Sci. 5:213–214, 1980.
6. Law, P.K. Beneficial effects of transplanting normal limb-bud mesenchyme into dystrophic mouse muscle. Muscle & Nerve 5: 619–627, 1982.
7. Law, P.K., T.G. Goodwin, and M.G. Wang. Normal myobast injections provide genetic treatment for murine dystrophy. Muscle & Nerve. 11:525–533, 1988.
8. Law, P.K., T.G. Goodwin, and H.J. Li. Histoincompatible myoblast injection improves muscle structure and function of dystrophic mice. Transplant Proc., 20:1114–1119, 1988.
9. Law, P.K., et al. Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy. Lancet, 336:114–115, 1990.
10. Law, P.K., T.G. Goodwin, Q. Fang, V. Duggirala, J.A. Florendo,D.S. Kirby, M.B. Deering, H.J. Li, M. Chen, T.J. Yoo, J. Cornett, L.M. Li, and R. L. Holcomb. Long-Term improvement in muscle function, structure and biochemistry following myoblast transfer in DMD. Acta Cardiomiologica, 3:281–301, 1991.
11. Chen, M., H.J. Li, Q.W. Fang, T.G. Goodwin, J.A. Florendo, and P.K. Law. Dystrophin cytochemistry in MDX mouse muscles injected with labeled normal myoblasts. Cell Transplantation 1:17–22, 1992.
12. Law, P.K., T.G. Goodwin, Q. Fang, V. Duggirala, C. Larkin, J. A. Florendo, D.S. Kirby, M.B. Deering, H.J. Li, M. Chen, T.J. Yoo, J. Cornett, L.M. Li, A. Shirzad, T. Quinley, and R.L. Holcomb. Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplantation 1:235–244, 1992.
13. Law, P.K. Myoblast transplantation. Science 257: 1329-30, 1992.
14. Law, P.K. Myoblast transfer therapy. Lancet 341:247, 1993.
15. Law, P.K., T.G. Goodwin, Q. Fang, M.B. Deering, V. Duggirala, C. Larkin, J.A. Florendo, D.S. Kirby, H.J. Li, M. Chen, J. Cornett, L. Li, A. Shirzad, T. Quinley, T.J. Yoo, R. Holcomb. Cell transplanation as an experimental treatment for Duchenne muscular dystrophy. Cell Transplantation 2:485-505, 1993.
16. Law, P.K., T.G. Goodwin, Q. Fang, M.B. Deering, V. Duggirala, C. Larkin, J.A. Florendo, J. Cornett, L. Li, A. Shirzad, T. Quinley, T.J. Yoo, R. Holcomb. Whole body myoblast transfer. Transpl Proc 26:3381-3383, 1994.
17. Law, P.K., H. Li, M. Chen, Q. Fang, T. Goodwin. Myoblast injection method regulates cell distribution and fusion. Transpl Proc 26:3417-3418, 1994.
18. Law, P.K., T.G. Goodwin, Q. Fang, T.L. Hall, T. Quinley, G. Vastagh, V. Duggirala, C. Larkin, J.A. Florendo, L. Li, T. Jackson, T.J. Yoo, N. Chase, M. Neel, T. Krahn, R. Holcomb. First human myoblast transfer therapy continues to show dystrophin after six years. Cell Transplantation 6:95-100, 1997.
19. Law, P.K., T.G. Goodwin, Q. Fang, T. Quinley, G. Vastagh, T. Hall, T. Jackson, M.B. Deering, V. Duggirala, C. Larkin, J.A. Florendo, L.M. Li, T.J. Yoo, N. Chase, M. Neel, T. Krahn, R.L. Holcomb. Human Gene Therapy with Myoblast Transfer. Transpl Proc 29:2234-2237, 1997.
20. Law, P.K., T.G. Goodwin, Q. Fang, G. Vastagh, T. Jordan, T. Jackson, S. Kenny, V. Duggirala, C. Larkin, N. Chase, W. Phillips, G. Williams, M. Neel, T. Krahn, R. Holcomb. Myoblast transfer as a platform technology of gene therapy. Gene Therapy and Molecular Biology 1:345-363, 1998.
21. Law P, Weinstein J, Ben Hain S et al. World’s first human myoblast transfer into the heart. Frontiers in Physiology 2000; A85.
22. Law, P.K., Nuclear Transfer and Human Genome Therapy. Business Briefing: Future Drug Discovery Genomics: 38-42, December 2001.
23. Law PK, Haider Kh., Fang G et al. Mechanisms of myoblast transfer in treating heart failure (2002) In: Kimchi, A., Ed., Advances in Heart Failure, Medimont, 43-48.
24. Law, P.K., The Regenerative Heart. Business Briefing: PharmaTech 2002 Drug Discovery: 65-71, April 2002.
25. Law, P.K., Concomitant Angiogenesis/Myogenesis in the Regenerative Heart. Business Briefing: Future Drug Discovery, Genomics: 64-67, October 2002.
26. Law PK, Haider K, Fang G, Jiang S, Chua F, Lim YT, Sim E. Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart. Mol Cell Biochem 2004, 263:173-8.
27. Law PK , Law DLM , Lu P, Guo J, Lu Y, Xue YF, and Li X. The world’s first myoblast study of Type II diabetic patients. Business Briefing: North American Pharmacotherapy 2004-Issue 2.